Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119

1.

Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes.

Hoffman EP, Riddle V, Siegler MA, Dickerson D, Backonja M, Kramer WG, Nagaraju K, Gordish-Dressman H, Damsker JM, McCall JM.

Steroids. 2018 Jun;134:43-52. doi: 10.1016/j.steroids.2018.02.010. Epub 2018 Mar 8.

2.
3.

Development and validation of Arabic version of the Neuropathic Pain Questionnaire-Short Form.

Terkawi AS, Backonja MM, Abolkhair A, Almaharbi S, Joy J, Foula F, Alswiti M, Terkawi YS, Al-Zhahrani T, Alghamdi FS, Tsang S.

Saudi J Anaesth. 2017 May;11(Suppl 1):S53-S62. doi: 10.4103/sja.SJA_86_17.

4.

Effect of Baseline Characteristics on the Pain Response to Pregabalin in Fibromyalgia Patients with Comorbid Depression.

Silverman SL, Backonja M, Pauer L, Landen J, Bhadra Brown P, Scavone JM, Vissing R, Clair A.

Pain Med. 2018 Mar 1;19(3):419-428. doi: 10.1093/pm/pnx091.

PMID:
28525632
5.

Pregabalin for the Treatment of Drug and Alcohol Withdrawal Symptoms: A Comprehensive Review.

Freynhagen R, Backonja M, Schug S, Lyndon G, Parsons B, Watt S, Behar R.

CNS Drugs. 2016 Dec;30(12):1191-1200. Review.

6.

Mindfulness Meditation-Based Intervention Is Feasible, Acceptable, and Safe for Chronic Low Back Pain Requiring Long-Term Daily Opioid Therapy.

Zgierska AE, Burzinski CA, Cox J, Kloke J, Singles J, Mirgain S, Stegner A, Cook DB, Bačkonja M.

J Altern Complement Med. 2016 Aug;22(8):610-20. doi: 10.1089/acm.2015.0314. Epub 2016 Jun 7.

7.

Intravenous abuse potential study of oxycodone alone or in combination with naltrexone in nondependent recreational opioid users.

Backonja M, Webster LR, Setnik B, Bass A, Sommerville KW, Matschke K, Malhotra BK, Wolfram G.

Am J Drug Alcohol Abuse. 2016 Sep;42(5):539-549. Epub 2016 May 21.

PMID:
27211522
8.

Mindfulness Meditation and Cognitive Behavioral Therapy Intervention Reduces Pain Severity and Sensitivity in Opioid-Treated Chronic Low Back Pain: Pilot Findings from a Randomized Controlled Trial.

Zgierska AE, Burzinski CA, Cox J, Kloke J, Stegner A, Cook DB, Singles J, Mirgain S, Coe CL, Bačkonja M.

Pain Med. 2016 Oct;17(10):1865-1881. Epub 2016 Mar 10.

9.

Managing Neuropathic Pain.

Jones RC 3rd, Lawson E, Backonja M.

Med Clin North Am. 2016 Jan;100(1):151-67. doi: 10.1016/j.mcna.2015.08.009. Epub 2015 Oct 28. Review.

PMID:
26614725
10.

Are Pain Ratings Irrelevant?

Bačkonja MM, Farrar JT.

Pain Med. 2015 Jul;16(7):1247-50. doi: 10.1111/pme.12748.

PMID:
26176790
11.

Relationships Among Pain Quality, Pain Impact, and Overall Improvement in Patients with Postherpetic Neuralgia Treated with Gastroretentive Gabapentin.

Freeman R, Wallace MS, Sweeney M, Backonja MM.

Pain Med. 2015 Oct;16(10):2000-11. doi: 10.1111/pme.12791. Epub 2015 Jun 25.

PMID:
26115203
12.

Opioids for chronic noncancer pain: A position paper of the American Academy of Neurology.

Katz JA, Swerdloff MA, Brass SD, Argoff CE, Markman J, Backonja M, Katz N.

Neurology. 2015 Apr 7;84(14):1503-4. doi: 10.1212/WNL.0000000000001485. No abstract available.

PMID:
25846999
13.

Intravenous lidocaine for neuropathic pain: a retrospective analysis of tolerability and efficacy.

Hutson P, Backonja M, Knurr H.

Pain Med. 2015 Mar;16(3):531-6. doi: 10.1111/pme.12642. Epub 2014 Dec 19.

PMID:
25530475
14.

Pharmacological and toxicological profile of opioid-treated, chronic low back pain patients entering a mindfulness intervention randomized controlled trial.

Zgierska A, Wallace ML, Burzinski CA, Cox J, Backonja M.

J Opioid Manag. 2014 Sep-Oct;10(5):323-35. doi: 10.5055/jom.2014.0222.

15.

Refractory Chronic Pain Screening Tool (RCPST): a feasibility study to assess practicality and validity of identifying potential neurostimulation candidates.

Baron R, Backonja MM, Eldridge P, Levy R, Vissers K, Attal N, Buchser E, Cruccu G, De Andrés J, Hansson P, Jacobs M, Loeser JD, Prager JP, Stanton Hicks M, Regnault A, Van den Abeele C, Taylor RS.

Pain Med. 2014 Feb;15(2):281-91. doi: 10.1111/pme.12272. Epub 2013 Nov 8.

PMID:
24524843
16.

Response to letter to the editor.

Dworkin RH, O'Connor AB, Kent J, Mackey SC, Raja SN, Stacey BR, Levy RM, Backonja M, Baron R, Harke H, Loeser JD, Treede RD, Turk DC, Wells CD.

Pain. 2014 May;155(5):1045-6. doi: 10.1016/j.pain.2014.01.029. Epub 2014 Feb 7. No abstract available.

PMID:
24513276
17.

Review of neuropathic pain screening and assessment tools.

Jones RC 3rd, Backonja MM.

Curr Pain Headache Rep. 2013 Sep;17(9):363. doi: 10.1007/s11916-013-0363-6. Review.

PMID:
23996692
18.

HIV neuropathy pain continues to pose a challenge.

Walk D, Backonja M.

Pain Med. 2013 Jul;14(7):957-8. doi: 10.1111/pme.12193. No abstract available.

PMID:
23855789
19.

Interventional management of neuropathic pain: NeuPSIG recommendations.

Dworkin RH, O'Connor AB, Kent J, Mackey SC, Raja SN, Stacey BR, Levy RM, Backonja M, Baron R, Harke H, Loeser JD, Treede RD, Turk DC, Wells CD; International Association for the Study of Pain Neuropathic Pain Special Interest Group.

Pain. 2013 Nov;154(11):2249-61. doi: 10.1016/j.pain.2013.06.004. Epub 2013 Jun 6. Review.

20.

Value of quantitative sensory testing in neurological and pain disorders: NeuPSIG consensus.

Backonja MM, Attal N, Baron R, Bouhassira D, Drangholt M, Dyck PJ, Edwards RR, Freeman R, Gracely R, Haanpaa MH, Hansson P, Hatem SM, Krumova EK, Jensen TS, Maier C, Mick G, Rice AS, Rolke R, Treede RD, Serra J, Toelle T, Tugnoli V, Walk D, Walalce MS, Ware M, Yarnitsky D, Ziegler D.

Pain. 2013 Sep;154(9):1807-19. doi: 10.1016/j.pain.2013.05.047. Epub 2013 Jun 3. Erratum in: Pain. 2014 Jan;155(1):205.

PMID:
23742795
21.

Sensory small fiber function differentially assessed with diode laser (DL) quantitative sensory testing (QST) in painful neuropathy (PN).

Moeller-Bertram T, Schilling JM, Bačkonja MM, Nemenov MI.

Pain Med. 2013 Mar;14(3):417-21. doi: 10.1111/pme.12049. Epub 2013 Feb 22.

PMID:
23433028
22.

Neuropathic pain therapy: from bench to bedside.

Backonja MM.

Semin Neurol. 2012 Jul;32(3):264-8. doi: 10.1055/s-0032-1329204. Epub 2012 Nov 1. Review.

PMID:
23117951
23.

Does the neurobiology of migraine make migraine patients "difficult"?

Bačkonja MM.

Headache. 2012 Nov-Dec;52(10):1611. doi: 10.1111/j.1526-4610.2012.02257.x. Epub 2012 Sep 27. Review. No abstract available.

PMID:
23016950
24.

Understanding chronic inflammatory and neuropathic pain.

Hughes JP, Chessell I, Malamut R, Perkins M, Bačkonja M, Baron R, Farrar JT, Field MJ, Gereau RW, Gilron I, McMahon SB, Porreca F, Rappaport BA, Rice F, Richman LK, Segerdahl M, Seminowicz DA, Watkins LR, Waxman SG, Wiech K, Woolf C.

Ann N Y Acad Sci. 2012 May;1255:30-44. doi: 10.1111/j.1749-6632.2012.06561.x.

PMID:
22564068
25.

Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations.

Dworkin RH, Turk DC, Peirce-Sandner S, Burke LB, Farrar JT, Gilron I, Jensen MP, Katz NP, Raja SN, Rappaport BA, Rowbotham MC, Backonja MM, Baron R, Bellamy N, Bhagwagar Z, Costello A, Cowan P, Fang WC, Hertz S, Jay GW, Junor R, Kerns RD, Kerwin R, Kopecky EA, Lissin D, Malamut R, Markman JD, McDermott MP, Munera C, Porter L, Rauschkolb C, Rice AS, Sampaio C, Skljarevski V, Sommerville K, Stacey BR, Steigerwald I, Tobias J, Trentacosti AM, Wasan AD, Wells GA, Williams J, Witter J, Ziegler D.

Pain. 2012 Jun;153(6):1148-58. doi: 10.1016/j.pain.2012.03.003. Epub 2012 Apr 9.

PMID:
22494920
26.

QST in peripheral nerve injury pain disorders.

Backonja MM, Walk D.

Pain. 2012 Apr;153(4):736-7. doi: 10.1016/j.pain.2012.02.009. Epub 2012 Mar 3. No abstract available.

PMID:
22386893
27.

Cognitive outcome of cerebral fat embolism.

Manousakis G, Han DY, Backonja M.

J Stroke Cerebrovasc Dis. 2012 Nov;21(8):906.e1-3. doi: 10.1016/j.jstrokecerebrovasdis.2011.07.006. Epub 2011 Oct 15.

PMID:
22001712
28.

Turning on the alarm: the neural mechanisms of the transition from innocuous to painful sensation.

Johnstone T, Salomons TV, Backonja MM, Davidson RJ.

Neuroimage. 2012 Jan 16;59(2):1594-601. doi: 10.1016/j.neuroimage.2011.08.083. Epub 2011 Sep 8.

29.

Gynecologic management of neuropathic pain.

Tu FF, Hellman KM, Backonja MM.

Am J Obstet Gynecol. 2011 Nov;205(5):435-43. doi: 10.1016/j.ajog.2011.05.011. Epub 2011 May 12. Review.

30.

NGX-4010, a capsaicin 8% dermal patch, administered alone or in combination with systemic neuropathic pain medications, reduces pain in patients with postherpetic neuralgia.

Irving G, Backonja M, Rauck R, Webster LR, Tobias JK, Vanhove GF.

Clin J Pain. 2012 Feb;28(2):101-7. doi: 10.1097/AJP.0b013e318227403d.

PMID:
21753727
31.

Efficacy of gabapentin enacarbil vs placebo in patients with postherpetic neuralgia and a pharmacokinetic comparison with oral gabapentin.

Backonja MM, Canafax DM, Cundy KC.

Pain Med. 2011 Jul;12(7):1098-108. doi: 10.1111/j.1526-4637.2011.01139.x. Epub 2011 May 31.

PMID:
21627766
32.

Evidence-based guideline: Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation.

Bril V, England J, Franklin GM, Backonja M, Cohen J, Del Toro D, Feldman E, Iverson DJ, Perkins B, Russell JW, Zochodne D; American Academy of Neurology; American Association of Neuromuscular and Electrodiagnostic Medicine; American Academy of Physical Medicine and Rehabilitation.

PM R. 2011 Apr;3(4):345-52, 352.e1-21. doi: 10.1016/j.pmrj.2011.03.008. Review.

PMID:
21497321
33.

Evidence-based guideline: treatment of painful diabetic neuropathy--report of the American Association of Neuromuscular and Electrodiagnostic Medicine, the American Academy of Neurology, and the American Academy of Physical Medicine & Rehabilitation.

Bril V, England JD, Franklin GM, Backonja M, Cohen JA, Del Toro DR, Feldman EL, Iverson DJ, Perkins B, Russell JW, Zochodne DW; American Academy of Neurology; American Asociation of Neuromuscular and Electrodiagnostic Medicine; American Academy of Physical Medicine and Rehabilitation.

Muscle Nerve. 2011 Jun;43(6):910-7. doi: 10.1002/mus.22092. Epub 2011 Apr 11.

34.

Evidence-based guideline: Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation.

Bril V, England J, Franklin GM, Backonja M, Cohen J, Del Toro D, Feldman E, Iverson DJ, Perkins B, Russell JW, Zochodne D; American Academy of Neurology; American Association of Neuromuscular and Electrodiagnostic Medicine; American Academy of Physical Medicine and Rehabilitation.

Neurology. 2011 May 17;76(20):1758-65. doi: 10.1212/WNL.0b013e3182166ebe. Epub 2011 Apr 11. Review. Erratum in: Neurology. 2011 Aug 9;77(6):603. Dosage error in article text.

35.

Impact of responder definition on the enriched enrollment randomized withdrawal trial design for establishing proof of concept in neuropathic pain.

Hewitt DJ, Ho TW, Galer B, Backonja M, Markovitz P, Gammaitoni A, Michelson D, Bolognese J, Alon A, Rosenberg E, Herman G, Wang H.

Pain. 2011 Mar;152(3):514-21. doi: 10.1016/j.pain.2010.10.050. Epub 2010 Dec 23.

PMID:
21185118
36.

A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia.

Irving GA, Backonja MM, Dunteman E, Blonsky ER, Vanhove GF, Lu SP, Tobias J; NGX-4010 C117 Study Group.

Pain Med. 2011 Jan;12(1):99-109. doi: 10.1111/j.1526-4637.2010.01004.x. Epub 2010 Nov 18.

PMID:
21087403
37.

Taking a peek into pain, from skin to brain with ENFD and QST.

Backonja MM, Lauria G.

Pain. 2010 Dec;151(3):559-60. doi: 10.1016/j.pain.2010.09.016. No abstract available.

PMID:
20937548
38.

NeuPSIG guidelines on neuropathic pain assessment.

Haanpää M, Attal N, Backonja M, Baron R, Bennett M, Bouhassira D, Cruccu G, Hansson P, Haythornthwaite JA, Iannetti GD, Jensen TS, Kauppila T, Nurmikko TJ, Rice AS, Rowbotham M, Serra J, Sommer C, Smith BH, Treede RD.

Pain. 2011 Jan;152(1):14-27. doi: 10.1016/j.pain.2010.07.031. Epub 2010 Sep 19. Review.

PMID:
20851519
39.

Combination drug therapy for chronic pain: a call for more clinical studies.

Mao J, Gold MS, Backonja MM.

J Pain. 2011 Feb;12(2):157-66. doi: 10.1016/j.jpain.2010.07.006. Epub 2010 Sep 17. Review.

40.

Maintenance of effect of duloxetine in patients with chronic low back pain: a 41-week uncontrolled, dose-blinded study.

Skljarevski V, Zhang S, Chappell AS, Walker DJ, Murray I, Backonja M.

Pain Med. 2010 May;11(5):648-57. doi: 10.1111/j.1526-4637.2010.00836.x. Epub 2010 Apr 13.

PMID:
20546509
41.

Future directions in neuropathic pain therapy: closing the translational loop.

Backonja M, Woolf CJ.

Oncologist. 2010;15 Suppl 2:24-9. doi: 10.1634/theoncologist.2009-S502. Review.

42.

Efficacy and safety of duloxetine in patients with chronic low back pain.

Skljarevski V, Desaiah D, Liu-Seifert H, Zhang Q, Chappell AS, Detke MJ, Iyengar S, Atkinson JH, Backonja M.

Spine (Phila Pa 1976). 2010 Jun 1;35(13):E578-85. doi: 10.1097/BRS.0b013e3181d3cef6.

PMID:
20461028
43.

NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled study with an open-label extension.

Backonja MM, Malan TP, Vanhove GF, Tobias JK; C102/106 Study Group.

Pain Med. 2010 Apr;11(4):600-8. doi: 10.1111/j.1526-4637.2009.00793.x. Epub 2010 Jan 22.

PMID:
20113411
44.

Assessment of neuropathic pain in primary care.

Haanpää ML, Backonja MM, Bennett MI, Bouhassira D, Cruccu G, Hansson PT, Jensen TS, Kauppila T, Rice AS, Smith BH, Treede RD, Baron R.

Am J Med. 2009 Oct;122(10 Suppl):S13-21. doi: 10.1016/j.amjmed.2009.04.006. Review.

PMID:
19801048
45.

Evolving pharmacological management of persistent pain in older persons.

Hanlon JT, Backonja M, Weiner D, Argoff C.

Pain Med. 2009 Sep;10(6):959-61. doi: 10.1111/j.1526-4637.2009.00698.x. Epub 2009 Sep 9. No abstract available.

PMID:
19744206
46.

Quantitative sensory testing in measurement of neuropathic pain phenomena and other sensory abnormalities.

Backonja MM, Walk D, Edwards RR, Sehgal N, Moeller-Bertram T, Wasan A, Irving G, Argoff C, Wallace M.

Clin J Pain. 2009 Sep;25(7):641-7. doi: 10.1097/AJP.0b013e3181a68c7e. Review.

PMID:
19692807
47.

Quantitative sensory testing and mapping: a review of nonautomated quantitative methods for examination of the patient with neuropathic pain.

Walk D, Sehgal N, Moeller-Bertram T, Edwards RR, Wasan A, Wallace M, Irving G, Argoff C, Backonja MM.

Clin J Pain. 2009 Sep;25(7):632-40. doi: 10.1097/AJP.0b013e3181a68c64. Review.

PMID:
19692806
48.

A randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of ABT-594 in patients with diabetic peripheral neuropathic pain.

Rowbotham MC, Duan WR, Thomas J, Nothaft W, Backonja MM.

Pain. 2009 Dec;146(3):245-52. doi: 10.1016/j.pain.2009.06.013. Epub 2009 Jul 24.

PMID:
19632048
49.

Developing neuropathic pain treatment guidelines for Asia Pacific.

Rosales R, Bashford G, Chaudakshetrin P, Kim U, Lee DI, Li CC, Meliala L, Ogawa S, Vijayan R, Wang SJ, Yeo AS, Backonja M.

Pain Pract. 2009 Jul-Aug;9(4):322-3. doi: 10.1111/j.1533-2500.2009.00285.x. No abstract available.

PMID:
19619268
50.

Pulsed electromagnetic fields to reduce diabetic neuropathic pain and stimulate neuronal repair: a randomized controlled trial.

Weintraub MI, Herrmann DN, Smith AG, Backonja MM, Cole SP.

Arch Phys Med Rehabil. 2009 Jul;90(7):1102-9. doi: 10.1016/j.apmr.2009.01.019.

PMID:
19577022

Supplemental Content

Loading ...
Support Center